ClinicalTrials.gg
RecruitingNCT07408024Updated Oct 1, 2026

Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis

A Phase 2 interventional study of TollB-001 and Placebo in Rheumatoid Arthritis (RA), sponsored by Toll Biotech Co. Ltd. (Beijing). Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Toll Biotech Co. Ltd. (Beijing) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2025, registered Jan 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 1, 2026Eligibility revisedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 249 studies in Arthritis, Rheumatoid with a site in China — 63 open to participants now, 72 under way, 3 of them phase 3. Arthritis, Rheumatoid · China.

Planned enrollment
185th of 217
24 · median 134
Started
2025
with 34 others
Phase 2
34 of 249
8 open now
Primary completion
2026-12
later than 33 of 71 live
Registered
233rd of 249
by date

Among the 249 studies in Arthritis, Rheumatoid with a site in China, this one is the 185th largest by planned enrollment of the 217 interventional ones that give a count, is one of 35 that started in 2025, is one of 34 in phase 2, reaches primary completion later than 33 of the 71 other live ones, and was the 233rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

63 of the 249 studies in Arthritis, Rheumatoid with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies in Arthritis, Rheumatoid with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the safety, pharmacokinetic (PK) characteristics, and preliminary efficacy of a new oral chemical drug in : adults aged 18-70 years (male or female) with moderate to severe active rheumatoid arthritis (RA), who have had inadequate response to or intolerance of at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs) .

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 to 70 years (inclusive) at the time of signing the form, regardless of gender.
  2. Diagnosis of RA according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.
  3. DAS28-CRP > 3.2 at screening.
  4. C-reactive protein (CRP)/high-sensitivity C-reactive protein (hsCRP) ≥ (ULN) at screening.
  5. Prior to the first administration of the study drug, has received continuous treatment with at least one conventional synthetic disease-modifying antirheumatic drug with inadequate response or intolerance, and agrees to discontinue use during the study.
  6. Female and male subjects of must use effective measures during the study and for 3 months after the last study drug administration. Male subjects whose spouses or partners are females of childbearing potential must also agree to use effective contraceptive measures during the study and for 3 months after the last administration, and shall not donate sperm during this period. Female subjects of childbearing potential must have a negative pregnancy test.
  7. Must provide written informed consent and be willing and able to comply with the study protocol (e.g., understand and complete questionnaires, follow the visit schedule, take medications as prescribed).

Exclusion criteria

Exclusion Criteria:

  1. to the study drug or any of its components.
  2. ACR functional class IV or being bedridden/wheelchair-bound for a long time.
  3. History or evidence of any of the following diseases:

    Other systemic inflammatory diseases except RA (excluding secondary Sjögren's syndrome), or other joint diseases that may affect efficacy evaluation (e.g., osteoarthritis with significant joint pain).

    Felty's syndrome. Any active malignant tumor or history of malignant tumor. Chronic pain history that may affect study evaluation. Active tuberculosis, latent untreated tuberculosis, or incompletely cured tuberculosis as judged by the investigator and/or specialist.

    History of any persistent or chronic infection. Poorly controlled severe diseases. Major surgery within 8 weeks before randomization or expected to undergo major surgery after enrollment.

  4. Positive surface antigen (HBsAg); or positive hepatitis B core antibody (HBcAb) with HBV DNA above the lower limit of detection; positive virus (HCV) antibody with positive HCV-RNA; positive (HIV) antibody or positive syphilis antibody.
  5. Drug or alcohol abuse or dependence at screening, or history of drug or alcohol abuse or dependence within 6 months before randomization.
  6. Participation in any clinical trial of drugs or medical devices within 4 weeks or 5 half-lives (whichever is longer) before randomization.
  7. Blood donation ≥ 400 mL or receipt of blood transfusion within 3 months before randomization.
  8. Any other factors deemed by the investigator to potentially affect the conduct or result evaluation of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    TollB-001 Low Dose

    Drug: TollB-001

  • Experimental
    TollB-001 Intermediate dose

    Drug: TollB-001

  • Experimental
    TollB-001 High dose

    Drug: TollB-001

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • TollB-001 Tablets

  • DrugPlacebo

    Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Safety-AE/lab tests/PE/VS/ECG

    Safety parameters including the incidence of adverse events (AEs), abnormalities in laboratory tests, physical examinations, vital signs, and routine 12-lead electrocardiograms

    Time frame: up to week 8

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's planned 15 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 12, 2026
StartActual
Sep 10, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites removed
Show 5 removed
  • The First Affiliated Hospital of Bengbu Medical College · Bengbu, China
  • Puyang Oilfield General Hospital · Puyang, China
  • Affiliated Hospital of Inner Mongolia Medical University · Hohhot, China
  • Pingxiang People's Hospital · Pingxiang, China
  • Linfen Central Hospital · Linfen, China
Oct 1, 2026
Eligibility
2 inclusion criteria edited; 2 exclusion criteria edited, 12 removed
What changed in the criteria
Inclusion criteria
  • ChangedBefore DAS28-CRP > 3.2 at screening (joints that have undergone major surgical treatment or intra-articular injection of glucocorticoids or hyaluronic acid within 6 weeks before randomization are not counted in the TJC and SJC counts).Now DAS28-CRP > 3.2 at screening.
  • EditedPrior to the first administration of the study drug, has received continuous treatment with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs, including methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, leflunomide, iguratimod) with inadequate response or intolerance, and agrees to discontinue use during the study.
Exclusion criteria
  • RemovedUse of any of the following drugs or treatments:
  • RemovedPrior use of Janus kinase (JAK) inhibitors (including but not limited to tofacitinib, baricitinib, upadacitinib), biologic disease-modifying antirheumatic drugs (bDMARDs), or participation in clinical trials of the aforementioned drugs.
  • RemovedUse of csDMARDs within 28 days before randomization (leflunomide within 56 days before administration, or subjects who have received standard cholestyramine treatment or activated charcoal washout within 28 days are not eligible for enrollment).
  • RemovedUse of other known drugs with strong immunosuppressive or immunomodulatory effects (such as puerarin, tripterygium wilfordii, mycophenolate mofetil, cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, etc.) other than the above within 4 weeks before randomization.
  • RemovedReceipt of any parenteral (intramuscular or intravenous) or intra-articular glucocorticoids within 4 weeks before randomization.
  • RemovedReceipt of interferon treatment within 4 weeks before randomization. Oral traditional Chinese medicine for the treatment of RA and other inflammatory diseases within 4 weeks before randomization.
  • RemovedUse of opioid drugs within 1 week or 5 drug half-lives (whichever is longer) before the first administration of the study drug.
  • RemovedReceipt of integrin αV antibodies or cell depletion therapy within 3 months or 5 half-lives (whichever is longer) before the screening visit.
  • EditedOther systemic inflammatory diseases except RA (excluding secondary Sjögren's syndrome), including but not limited to juvenile chronic arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, reactive arthritis, systemic vasculitis, gout, or other joint diseases that may affect efficacy evaluation (e.g., osteoarthritis with significant joint pain).
  • RemovedHistory of any persistent or chronic infection (e.g., chronic pyelonephritis, bronchiectasis, osteomyelitis) deemed inappropriate for study participation by the investigator, or oral anti-infective drugs (excluding onychomycosis) within 14 days before the first administration of the study drug; history of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks before the screening visit.
  • RemovedPoorly controlled severe diseases such as diabetes mellitus, hypertension, kidney disease, neurological disease, liver disease, severe heart disease (e.g., decompensated heart failure [New York Heart Association Class III or IV], unstable angina pectoris, myocardial infarction, etc.), respiratory disease, severe chronic gastrointestinal disease (e.g., active or recurrent peptic ulcer), or prior treatment that may affect drug absorption (e.g., gastrointestinal surgery) and deemed by the investigator to potentially hinder the subject's participation in the study.
  • EditedHistory of any persistent or chronic infection. Poorly controlled severe diseases. Major surgery within 8 weeks before randomization or expected to undergo major surgery after enrollment.
  • RemovedAny laboratory abnormalities meeting the following criteria at screening:
  • RemovedHemoglobin < 90.0 g/L. Total white blood cell count < 2.5 × 10⁹/L. Neutrophil count < 1.5 × 10⁹/L. Lymphopenia (lymphocyte count < 750 cells/μL). Platelet count < 100 × 10⁹/L.
Oct 1, 2026
Interventions
Changed Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po→TollB-001. Arm changed TollB-001→TollB-001 Low Dose. Arms added: TollB-001 Intermediate dose·TollB-001 High dose
Oct 1, 2026
Secondary outcomes
12 removed
What changed in the outcomes
  • RemovedEfficacy-ACR20Time frame: Day8, Day15, Day29, Day56
  • RemovedEfficacyACR50/70Time frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-DAS28Time frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-CDAITime frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-morning stiffnessTime frame: Day8, Day15, Day29, Day56
  • RemovedEfficay-patient assessment of arthritis painTime frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-patient global assessmentTime frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-physician's global assessemntTime frame: Day8, Day15, Day29, Day56
  • RemovedEfficacy-DAQ-DITime frame: Day8, Day15, Day29, Day56
  • RemovedEfficay-ESRTime frame: Day8, Day15, Day29, Day56
  • RemovedEfficay-CRPTime frame: Day8, Day15, Day29, Day56
  • RemovedSecondaryTime frame: Up to week 4
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    5 sites removed
    Show 5 removed
    • The First Affiliated Hospital of Bengbu Medical College · Bengbu, China
    • Puyang Oilfield General Hospital · Puyang, China
    • Affiliated Hospital of Inner Mongolia Medical University · Hohhot, China
    • Pingxiang People's Hospital · Pingxiang, China
    • Linfen Central Hospital · Linfen, China
    Eligibility 2 inclusion criteria edited; 2 exclusion criteria edited, 12 removed
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore DAS28-CRP > 3.2 at screening (joints that have undergone major surgical treatment or intra-articular injection of glucocorticoids or hyaluronic acid within 6 weeks before randomization are not counted in the TJC and SJC counts).Now DAS28-CRP > 3.2 at screening.
    • EditedPrior to the first administration of the study drug, has received continuous treatment with at least one conventional synthetic disease-modifying antirheumatic drug (csDMARDs, including methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, leflunomide, iguratimod) with inadequate response or intolerance, and agrees to discontinue use during the study.
    Exclusion criteria
    • RemovedUse of any of the following drugs or treatments:
    • RemovedPrior use of Janus kinase (JAK) inhibitors (including but not limited to tofacitinib, baricitinib, upadacitinib), biologic disease-modifying antirheumatic drugs (bDMARDs), or participation in clinical trials of the aforementioned drugs.
    • RemovedUse of csDMARDs within 28 days before randomization (leflunomide within 56 days before administration, or subjects who have received standard cholestyramine treatment or activated charcoal washout within 28 days are not eligible for enrollment).
    • RemovedUse of other known drugs with strong immunosuppressive or immunomodulatory effects (such as puerarin, tripterygium wilfordii, mycophenolate mofetil, cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, etc.) other than the above within 4 weeks before randomization.
    • RemovedReceipt of any parenteral (intramuscular or intravenous) or intra-articular glucocorticoids within 4 weeks before randomization.
    • RemovedReceipt of interferon treatment within 4 weeks before randomization. Oral traditional Chinese medicine for the treatment of RA and other inflammatory diseases within 4 weeks before randomization.
    • RemovedUse of opioid drugs within 1 week or 5 drug half-lives (whichever is longer) before the first administration of the study drug.
    • RemovedReceipt of integrin αV antibodies or cell depletion therapy within 3 months or 5 half-lives (whichever is longer) before the screening visit.
    • EditedOther systemic inflammatory diseases except RA (excluding secondary Sjögren's syndrome), including but not limited to juvenile chronic arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, reactive arthritis, systemic vasculitis, gout, or other joint diseases that may affect efficacy evaluation (e.g., osteoarthritis with significant joint pain).
    • RemovedHistory of any persistent or chronic infection (e.g., chronic pyelonephritis, bronchiectasis, osteomyelitis) deemed inappropriate for study participation by the investigator, or oral anti-infective drugs (excluding onychomycosis) within 14 days before the first administration of the study drug; history of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks before the screening visit.
    • RemovedPoorly controlled severe diseases such as diabetes mellitus, hypertension, kidney disease, neurological disease, liver disease, severe heart disease (e.g., decompensated heart failure [New York Heart Association Class III or IV], unstable angina pectoris, myocardial infarction, etc.), respiratory disease, severe chronic gastrointestinal disease (e.g., active or recurrent peptic ulcer), or prior treatment that may affect drug absorption (e.g., gastrointestinal surgery) and deemed by the investigator to potentially hinder the subject's participation in the study.
    • EditedHistory of any persistent or chronic infection. Poorly controlled severe diseases. Major surgery within 8 weeks before randomization or expected to undergo major surgery after enrollment.
    • RemovedAny laboratory abnormalities meeting the following criteria at screening:
    • RemovedHemoglobin < 90.0 g/L. Total white blood cell count < 2.5 × 10⁹/L. Neutrophil count < 1.5 × 10⁹/L. Lymphopenia (lymphocyte count < 750 cells/μL). Platelet count < 100 × 10⁹/L.
    Secondary outcomes 12 removed
    What changed in the outcomes
    • RemovedEfficacy-ACR20Time frame: Day8, Day15, Day29, Day56
    • RemovedEfficacyACR50/70Time frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-DAS28Time frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-CDAITime frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-morning stiffnessTime frame: Day8, Day15, Day29, Day56
    • RemovedEfficay-patient assessment of arthritis painTime frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-patient global assessmentTime frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-physician's global assessemntTime frame: Day8, Day15, Day29, Day56
    • RemovedEfficacy-DAQ-DITime frame: Day8, Day15, Day29, Day56
    • RemovedEfficay-ESRTime frame: Day8, Day15, Day29, Day56
    • RemovedEfficay-CRPTime frame: Day8, Day15, Day29, Day56
    • RemovedSecondaryTime frame: Up to week 4
    Interventions Changed Group 1: TollB-001 100mg qd po; Group 2: TollB-001 200mg qd po; Group 3: TollB-001400mg qd po→TollB-001. Arm changed TollB-001→TollB-001 Low Dose. Arms added: TollB-001 Intermediate dose·TollB-001 High dose
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences · Beijing, ChinaContact removed (no phone or email listed)Contact removed (no phone or email listed)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07408024
Lead sponsor
Toll Biotech Co. Ltd. (Beijing)
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Sep 10, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

Weili Wang
Contact
wangweili@toll-biotech.com
+86 10 80710966

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TOLLB-001

Start the discussion